Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer.

This article discusses a study that explores a new strategy for constructing circular RNA (circRNA) called NeoAna, which enhances the sensitivity of non-small cell lung cancer (NSCLC) to the drug Osimertinib. The researchers successfully designed and synthesized circRNAs without scar sequences, and they observed the formation of circRNA and successful protein translation in cells. They also restored the expression of the tumor suppressor PTEN using the NeoAna system, which increased sensitivity to Osimertinib and induced apoptosis in Osimertinib-resistant cells. The researchers further demonstrated the efficacy of the NeoAna system in animal models. Overall, this study suggests that engineered circRNA can enhance the effectiveness of Osimertinib in treating NSCLC. The article also discusses the potential mechanisms of PTEN in enhancing the sensitivity of Osimertinib, a drug used to treat NSCLC. The study used RNA-seq to identify common genes between Osimertinib-resistant cells and cells with restored PTEN expression, and found that AKR1C2, a gene involved in drug resistance, was in line with the RNA-seq results. The study also explored the use of a circRNA platform called NeoAna to restore PTEN expression and overcome Osimertinib resistance, suggesting that this platform could be a promising strategy for RNA-based therapeutics. [Extracted from the article]